CN109863172B - 抗vegf-a抗体及其用途 - Google Patents

抗vegf-a抗体及其用途 Download PDF

Info

Publication number
CN109863172B
CN109863172B CN201780064561.XA CN201780064561A CN109863172B CN 109863172 B CN109863172 B CN 109863172B CN 201780064561 A CN201780064561 A CN 201780064561A CN 109863172 B CN109863172 B CN 109863172B
Authority
CN
China
Prior art keywords
antibody
binding
vegf
binding molecule
lcdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780064561.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109863172A (zh
Inventor
C.C.廖
N.迪马西
K.科夫曼
崔平
高长寿
M.A.塞佩达
A.施瓦茨米特尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of CN109863172A publication Critical patent/CN109863172A/zh
Application granted granted Critical
Publication of CN109863172B publication Critical patent/CN109863172B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780064561.XA 2016-08-23 2017-08-22 抗vegf-a抗体及其用途 Active CN109863172B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378391P 2016-08-23 2016-08-23
US62/378391 2016-08-23
PCT/EP2017/071106 WO2018037001A1 (en) 2016-08-23 2017-08-22 Anti-vegf-a antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN109863172A CN109863172A (zh) 2019-06-07
CN109863172B true CN109863172B (zh) 2022-08-26

Family

ID=59677248

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780064561.XA Active CN109863172B (zh) 2016-08-23 2017-08-22 抗vegf-a抗体及其用途

Country Status (10)

Country Link
US (2) US10919958B2 (enExample)
EP (2) EP3783022A3 (enExample)
JP (2) JP6949106B2 (enExample)
KR (1) KR102538827B1 (enExample)
CN (1) CN109863172B (enExample)
AU (2) AU2017315076B2 (enExample)
CA (1) CA3034576A1 (enExample)
ES (1) ES2836286T3 (enExample)
IL (1) IL264961B2 (enExample)
WO (1) WO2018037001A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7485273B2 (ja) * 2020-06-25 2024-05-16 国立大学法人 鹿児島大学 抗ｖｅｇｆ－ａ抗体による癌に対する治療応答性を予測又は決定するための方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1259962A (zh) * 1997-04-07 2000-07-12 基因技术股份有限公司 抗－血管内皮生长因子的抗体
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN102006885A (zh) * 2006-10-20 2011-04-06 先灵公司 完全人源抗vegf抗体及其使用方法
CN102276722A (zh) * 2011-01-14 2011-12-14 中国科学院北京基因组研究所 新型血管内皮生长因子人源化单克隆抗体
CN103562222A (zh) * 2011-04-01 2014-02-05 勃林格殷格翰国际有限公司 结合VEGF和Ang2的双特异性结合分子

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP2338915A3 (en) * 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2604280A3 (en) * 2008-03-27 2013-10-16 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
ES2749349T3 (es) * 2011-11-07 2020-03-19 Medimmune Llc Proteínas de unión multiespecíficas y multivalentes y usos de las mismas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1259962A (zh) * 1997-04-07 2000-07-12 基因技术股份有限公司 抗－血管内皮生长因子的抗体
CN102006885A (zh) * 2006-10-20 2011-04-06 先灵公司 完全人源抗vegf抗体及其使用方法
WO2010124009A2 (en) * 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
CN102276722A (zh) * 2011-01-14 2011-12-14 中国科学院北京基因组研究所 新型血管内皮生长因子人源化单克隆抗体
CN103562222A (zh) * 2011-04-01 2014-02-05 勃林格殷格翰国际有限公司 结合VEGF和Ang2的双特异性结合分子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy;Ferrara, N 等;《Biochemical and Biophysical Research Communications》;20050602;第333卷(第02期);328-335 *
抗VEGF/VEGFR靶向肿瘤血管药物的研究进展;李伊培等;《现代生物医学进展》;20140610;第14卷(第16期);3158-3162 *
靶向肿瘤血管形成的抗肿瘤作用及药物研究进展;宣自学等;《中国新药杂志》;20140219;第23卷(第03期);282-288 *

Also Published As

Publication number Publication date
AU2017315076B2 (en) 2020-10-08
EP3504236B1 (en) 2020-09-23
JP2019528074A (ja) 2019-10-10
AU2020289850A1 (en) 2021-01-28
US10919958B2 (en) 2021-02-16
JP7277531B2 (ja) 2023-05-19
AU2020289850B2 (en) 2024-06-06
JP6949106B2 (ja) 2021-10-13
US11634483B2 (en) 2023-04-25
KR20190040029A (ko) 2019-04-16
AU2017315076A1 (en) 2019-04-04
EP3783022A2 (en) 2021-02-24
IL264961B2 (en) 2025-02-01
JP2022008447A (ja) 2022-01-13
EP3783022A3 (en) 2021-06-30
CN109863172A (zh) 2019-06-07
IL264961A (enExample) 2019-04-30
IL264961B1 (en) 2024-10-01
US20210147531A1 (en) 2021-05-20
CA3034576A1 (en) 2018-03-01
US20190202903A1 (en) 2019-07-04
KR102538827B1 (ko) 2023-05-31
WO2018037001A1 (en) 2018-03-01
ES2836286T3 (es) 2021-06-24
EP3504236A1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
JP6891217B2 (ja) 抗ｎｇｆ抗体およびその使用
US11566068B2 (en) Nucleic acids encoding bispecific anti-VEGF and anti-ANG2 antibodies and uses thereof
JP7277531B2 (ja) 抗ｖｅｇｆ－ａ抗体ならびにそれらの使用
CN117043187A (zh) GARP/TGFβ1抗体及其应用
HK40008333B (en) Anti-vegf-a antibodies and uses thereof
HK40047851A (en) Anti-vegf-a antibodies and uses thereof
HK40008333A (en) Anti-vegf-a antibodies and uses thereof
HK40010498B (en) Anti-vegf-a antibodies and uses thereof
HK40010498A (en) Anti-vegf-a antibodies and uses thereof
HK40008334A (en) Anti-vegf-a and anti-ang2 antibodies and uses thereof
HK40008334B (zh) 抗vegf-a和抗ang2抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008333

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant